Journal
REVUE NEUROLOGIQUE
Volume 177, Issue 7, Pages 785-790Publisher
MASSON EDITEUR
DOI: 10.1016/j.neurol.2021.06.003
Keywords
CGRP; Receptors; CLR; RAMPs; CTR
Categories
Ask authors/readers for more resources
Migraine treatment has entered a new era with drugs targeting CGRP showing significant improvements over existing options, potentially becoming effective treatments for both acute and chronic migraines.
Migraine treatment has reached a new era with the development of drugs that target the trigeminal neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. The CGRP related therapies offer considerable improvements over existing drugs as they are the first to be designed to act on the trigeminal pain system, more specific and with few adverse events. Small molecule CGRP receptor antagonists, such as rimegepant and ubrogepant, are effective for the acute treatment of migraine headache. In contrast, monoclonal antibodies against CGRP or the CGRP receptor are beneficial for the prophylactic treatments in chronic migraine. Here I will provide a historical overview of the long path that led to their successful development. In addition, I will discuss aspects on the biology of CGRP signalling, the role of CGRP in migraine headache, the efficacy of CGRP targeted treatment, and synthesize what currently is known about the role of CGRP in the trigeminovascular system. (C) 2021 The Author. Published by Elsevier Masson SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available